Oxycodone/Naloxone Nordic Drugs

Active Ingredient:: Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate
Origin:: EU

Oxycodone/Naloxone Nordic Drugs (Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, the active ingredient in Oxycodone/Naloxone Nordic Drugs, is an opioid analgesic presented as a combination tablet for oral use. It treats moderate to severe pain in adult patients when an opioid analgesic is required. GNH India supplies Oxycodone/Naloxone Nordic Drugs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH India supplies Oxycodone/Naloxone Nordic Drugs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Nordic Drugs Ab

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxycodone/Naloxone is used primarily for pain management within the opioid pathway.

Chronic non‑cancer pain: provides opioid analgesia while reducing opioid‑induced constipation.
Cancer‑related pain: delivers strong pain relief in patients with advanced disease.
Post‑operative pain: controls acute pain after major surgery when rapid, effective analgesia is needed.
Severe musculoskeletal pain: alleviates intense pain from conditions such as severe osteoarthritis or rheumatoid arthritis.
Pain associated with palliative care: improves comfort in end‑of‑life settings.

How It Works

Oxycodone binds to µ‑opioid receptors in the central nervous system, producing analgesia by inhibiting pain signal transmission. Naloxone, a peripheral opioid antagonist, remains largely inactive when taken orally but blocks µ‑receptors in the gastrointestinal tract, counteracting opioid‑induced constipation without diminishing central analgesic effects.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

Nausea and vomiting: mild to moderate gastrointestinal upset.
Constipation: reduced bowel motility despite naloxone's protective effect.
Dizziness or light‑headedness: transient sensation of unsteadiness.
Drowsiness or somnolence: increased sleepiness, especially after dose initiation.
Dry mouth: reduced salivary flow causing oral discomfort.
Pruritus: mild itching, often localized.

Serious or Rare Side Effects

Respiratory depression: slowed breathing that can be life‑threatening.
Severe hypotension: marked drop in blood pressure leading to fainting.
Opioid dependence or addiction: risk of misuse with prolonged therapy.
Hepatic impairment: elevated liver enzymes indicating liver stress.
Allergic reactions: rash, swelling, or anaphylaxis in susceptible individuals.
Withdrawal symptoms: abrupt discontinuation may trigger opioid withdrawal signs.

Precautions & Warnings

When prescribing Oxycodone/Naloxone, clinicians should consider several safety measures.

Assess pain severity: confirm that opioid therapy is appropriate for the patient’s level of pain.
Evaluate gastrointestinal risk: monitor for constipation despite naloxone’s protective role.
Screen for respiratory conditions: patients with COPD or sleep‑apnea need close observation.
Review medication history: avoid concurrent use with other central nervous system depressants.
Counsel on dependence: educate patients about the potential for addiction and proper use.
Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Avoid Interactions

Oxycodone/Naloxone can interact with a range of medicines, requiring careful management.

Major Interactions (Avoid)

Benzodiazepines: combined CNS depression can cause profound respiratory depression.
MAO inhibitors: risk of severe serotonin syndrome and hypertensive crisis.
Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase oxycodone plasma levels, heightening toxicity.

Moderate Interactions (Monitor Closely)

CNS depressants (e.g., antihistamines, muscle relaxants): may enhance sedation and dizziness.
CYP2D6 inhibitors (e.g., fluoxetine): can alter oxycodone metabolism, affecting analgesic response.
Diuretics: may exacerbate hypotension when combined with opioid‑induced vasodilation.

Frequently Asked Questions

Oxycodone/Naloxone is indicated for the management of moderate to severe pain, including chronic non‑cancer pain, cancer‑related pain, post‑operative pain, severe musculoskeletal pain, and pain in palliative‑care settings. The combination provides strong analgesia while helping to reduce opioid‑induced constipation.

Oxycodone acts as an agonist at µ‑opioid receptors in the central nervous system, decreasing the perception of pain by inhibiting the transmission of nociceptive signals. Naloxone remains largely inactive systemically when taken orally but blocks peripheral µ‑receptors in the gastrointestinal tract, mitigating constipation without diminishing central pain relief.

The specific dose of Oxycodone/Naloxone is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, renal and hepatic function, and overall clinical condition. Dosage adjustments are individualized and should follow local prescribing guidelines.

Oxycodone/Naloxone is generally classified as contraindicated or used with caution during pregnancy because opioids can affect fetal development and cause neonatal withdrawal. It is also excreted in breast milk, so breastfeeding mothers should discuss risks and alternatives with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Compared with single‑agent opioids, the Oxycodone/Naloxone combination offers comparable analgesic potency while reducing the incidence of opioid‑induced constipation. It does not replace other opioids for patients without constipation concerns, and selection should consider individual patient needs and tolerability.

Store the tablets at ambient temperature, preferably below 25°C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and unauthorized persons.

The medication is supplied as oral tablets and should be taken whole with water, usually once or twice daily as directed by the prescriber. Swallowing the tablet whole ensures proper release of both oxycodone and naloxone.

The most serious risks include respiratory depression, severe hypotension, opioid dependence or addiction, and rare but life‑threatening allergic reactions. Patients should be monitored closely, especially during dose initiation and when combined with other central nervous system depressants.

Patients with known hypersensitivity to oxycodone, naloxone, or any excipients, those with severe respiratory depression, acute or severe asthma, or untreated obstructive sleep apnea should avoid this medication. It is also contraindicated in individuals taking MAO inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.